The Food and Drug Administration on Wednesday authorized Novavax’s protein-based Covid vaccine for adults, providing Americans with an alternative to the mRNA-based shots from Pfizer-BioNTech and Moderna.
The Novavax primary series is given in two doses, administered 21 days apart.
Full coverage of the coronavirus outbreak
“Today’s authorization offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization,” FDA Commissioner Dr. Robert Califf said in a statement.